Conexeu Sciences Inc. (CNXU) is an innovative biotechnology company committed to enhancing healthcare through the development of advanced diagnostics and therapeutics. Leveraging cutting-edge technology, Conexeu aims to deliver products that not only improve patient outcomes but also lower healthcare costs. With a robust emphasis on research and development, the company stands at the forefront of significant medical advancements, positioning itself as an attractive investment opportunity in the burgeoning biotech sector. Through strategic collaborations and a diverse product pipeline, Conexeu is focused on addressing critical unmet medical needs, appealing to institutional investors looking to engage with breakthrough health solutions.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-7.20M |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.34 |
| Price-to-Book | 28.52 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $26.76M |
| Float | $15.56M |
| % Insiders | 40.98% |
| % Institutions | 0.00% |
Highlights An unclaimed opportunity. Large-volume body contouring, and restoration of the breasts, hips, and buttocks is a significant injectable aesthetics category yet to be claimed.
Study Highlights P.R.O.O.F study complete, marking an important catalyst. Conexeu has completed its P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) preclinical program, which provides the evidence base behind the CXU™ platform's development direction and the Company's planned move into the medical aesthetics injectable market.
Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre
Conexeu Sciences is rated Buy, leveraging a patented CXU platform targeting multi-billion-dollar regenerative medicine markets with a flagship wound care product. CNXU's Ten-Minute Tissue™ aims for FDA 510(k) clearance by Q1 2027, potentially accelerating market entry to late 2027 and minimizing investor dilution. Current valuation (~$13.20/share) exceeds risk-adjusted fair value ($10.71), but premium is justified by pipeline breadth and upside if regulatory milestones are met.
Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution
RENO, Nev., June 03, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, will ring the Nasdaq Closing Bell on Wednesday, June 10, 2026, at the Nasdaq MarketSite in New York City in celebration of its recent public listing and the commencement of
Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology
Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CNXU and any ticker you trade — then tracks every position and per-strategy win rate.
